Anika Therapeutics (NASDAQ:ANIK) will be announcing its earnings results after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of $0.44 per share for the quarter.

Shares of Anika Therapeutics (NASDAQ ANIK) opened at $57.24 on Wednesday. Anika Therapeutics has a 52 week low of $41.64 and a 52 week high of $69.81. The company has a market capitalization of $839.24, a price-to-earnings ratio of 27.00, a price-to-earnings-growth ratio of 3.49 and a beta of 1.60.

Several analysts have commented on ANIK shares. Barrington Research reiterated a “buy” rating and set a $57.00 target price on shares of Anika Therapeutics in a research note on Thursday, December 28th. Sidoti assumed coverage on Anika Therapeutics in a research note on Friday, January 26th. They issued a “buy” rating on the stock. BidaskClub downgraded Anika Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, December 14th. Finally, First Analysis upgraded Anika Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $45.00 to $68.00 in a research note on Wednesday, January 24th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Anika Therapeutics has a consensus rating of “Buy” and an average price target of $62.50.

In other news, insider Richard Hague sold 5,250 shares of the firm’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $54.48, for a total value of $286,020.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 6.57% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Earnings History for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with's FREE daily email newsletter.